E2100, published in the 2007 issue of the new England Journal of medicine, has laid an important foundation for the combination of antiangio
E2100, published in the 2007 issue of the new England Journal of medicine, has laid an important foundation for the combination of antiangiogenic drugs and first-line treatment of metastatic breast cancer. Study on the phase III confirmed that adding paclitaxel bevacizumab can make mBC patients with prolonged progression free survival (5.8 months versus 11.4 months, P < 0.0001 objective efficiency doubled, 50% to 22%, P < 0.0001. And this combination did not significantly increase side effects, good safety. Someone introduced the significance of the research on the tips for human epidermal growth factor receptor 2 negative breast cancer patients, will no longer consider chemotherapy drugs, can also be considered combined with anti angiogenesis therapy and chemotherapy, which will further increase the choice of clinical treatment.
On this basis, the AVADO study released in 2008 by the substantial evidence of bevacizumab combined with paclitaxel. Study on the phase III in addition to observe the efficacy and safety of bevacizumab combined with a taxane docetaxel, also discussed the different doses of bevacizumab. Research shows that for HER2 negative mBC patients, low dose and high dose of bevacizumab plus docetaxel PFS were significantly prolonged compared with control group, the subgroup of PFS is basically the same benefit.